Spero Therapeutics Inc (NASDAQ:SPRO) has a beta value of 0.67 and has seen 90543.0 shares traded in the last trading session. The company, currently valued at $44.43M, closed the last trade at $0.81 per share which meant it lost -$0.01 on the day or -0.21% during that session. The SPRO stock price is -133.33% off its 52-week high price of $1.89 and 8.64% above the 52-week low of $0.74. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.34 million shares traded. The 3-month trading volume is 256.82K shares.
The consensus among analysts is that Spero Therapeutics Inc (SPRO) is Buy stock at the moment, with a recommendation rating of 2.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.31.
Spero Therapeutics Inc (NASDAQ:SPRO) trade information
Sporting -0.21% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the SPRO stock price touched $0.81 or saw a rise of 3.5%. Year-to-date, Spero Therapeutics Inc shares have moved -20.87%, while the 5-day performance has seen it change -0.42%. Over the past 30 days, the shares of Spero Therapeutics Inc (NASDAQ:SPRO) have changed -9.16%. Short interest in the company has seen 0.38 million shares shorted with days to cover at 1.84.
Spero Therapeutics Inc (SPRO) estimates and forecasts
Figures show that Spero Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -33.20% over the past 6 months, with this year growth rate of -379.07%, compared to 15.30% for the industry. Revenue growth from the last financial year stood is estimated to be -62.45%.
2 analysts offering their estimates for the company have set an average revenue estimate of 6.2M for the current quarter. 1 have an estimated revenue figure of 11M for the next ending quarter. Year-ago sales stood 73.52M and 9.27M respectively for this quarter and the next, and analysts expect sales will shrink by -91.57% for the current quarter and -62.45% for the next.
SPRO Dividends
Spero Therapeutics Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Spero Therapeutics Inc (NASDAQ:SPRO)’s Major holders
Insiders own 24.47% of the company shares, while shares held by institutions stand at 25.46% with a share float percentage of 33.70%. Investors are also buoyed by the number of investors in a company, with Spero Therapeutics Inc having a total of 59.0 institutions that hold shares in the company. The top two institutional holders are ANSON FUNDS MANAGEMENT LP with over 3.75 million shares worth more than $4.88 million. As of 2024-06-30, ANSON FUNDS MANAGEMENT LP held 7.007% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 1.77 million shares as of 2024-06-30. The firm’s total holdings are worth over $2.3 million and represent 3.3079% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Sep 30, 2024, the former fund manager holds about 2.14% shares in the company for having 1.17 shares of worth $0.95 million while later fund manager owns 587.34 shares of worth $0.48 million as of Sep 30, 2024, which makes it owner of about 1.08% of company’s outstanding stock.
